Adelstein D J, Hines J D
Cancer. 1985 Aug 1;56(3):467-71. doi: 10.1002/1097-0142(19850801)56:3<467::aid-cncr2820560309>3.0.co;2-0.
Bone marrow aspirates and biopsy specimens were examined from seven patients with small cell lung cancer. All patients had received recent combination chemotherapy including VP-16. No correlation between marrow biopsy cellularity and hematologic toxicity could be established. However, an unusual combination of morphologic changes was seen. This included an initial rapid increase in the M:E ratio, interference with cell division, and eventual cell death. There was little evidence of mitotic arrest or megaloblastosis. These changes are consistent with the known mechanism of action of VP-16, the only agent given to all patients. The small sample size and the unknown contributions of the other cytotoxic agents administered allow only limited conclusions.
对7例小细胞肺癌患者的骨髓穿刺物和活检标本进行了检查。所有患者近期均接受了包括VP - 16在内的联合化疗。骨髓活检细胞密度与血液学毒性之间未发现相关性。然而，观察到了一种不寻常的形态学变化组合。这包括M:E比值最初迅速升高、细胞分裂受到干扰以及最终细胞死亡。几乎没有有丝分裂停滞或巨幼细胞贫血的证据。这些变化与VP - 16已知的作用机制一致，VP - 16是所有患者都使用过的唯一药物。样本量小以及所给予的其他细胞毒性药物的作用不明，因此只能得出有限的结论。
